Eton Pharmaceuticals, Inc. (ETON)
ETON moved a median of -0.34% 30 minutes after news, and -0.74% by the close. How ETON actually reacts to news — the realized, point-in-time move the market made, measured across 234 labeled events over the last three years with zero look-ahead.
ETON’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 224 |
| 30-min | -0.34% | 40% | 234 |
| 60-min | -0.58% | 41% | 234 |
| to close | -0.74% | 42% | 231 |
| Middle 50% of ETON reactions | -1.42% to +1.00% |
|---|---|
| Median reaction (30-min) | -0.34% |
| Measured reactions | 234 |
Half of all Eton Pharmaceuticals, Inc. news events land between -1.42% and +1.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ETON reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 40 | +0.10% | 58% | +1.21% |
| Price-target raises | 13 | -0.17% | 46% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ETON ranks against every other measured name →
That’s how ETON usually reacts — get an email when it moves on news →Email me when ETON moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ETON's baseline. Nothing else.
Recent ETON events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film | Press release | GlobeNewswire | +0.76% | -1.16% | |
| Form 8-K Eton Pharmaceuticals, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | -1.16% | |
| Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules | Press release | GlobeNewswire | -0.43% | +2.60% | |
| Form 8-K Eton Pharmaceuticals, For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +2.60% | |
| Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference | Press release | GlobeNewswire | +0.00% | +0.27% | |
| Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +3.00% | +6.88% | |
| Form 10-Q Eton Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.00% | +6.88% | |
| Form 8-K Eton Pharmaceuticals, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | +6.88% | |
| Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 | Press release | GlobeNewswire | -0.68% | -4.17% | |
| Form 8-K Eton Pharmaceuticals, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -4.17% | |
| Form 8-K Eton Pharmaceuticals, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +1.64% | |
| Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 | Press release | GlobeNewswire | -1.91% | -2.97% | |
| Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution | Press release | GlobeNewswire | +0.80% | +3.35% | |
| Form 8-K Eton Pharmaceuticals, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +3.35% | |
| Form 8-K Eton Pharmaceuticals, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.77% | +0.81% | |
| Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) | Press release | GlobeNewswire | -1.20% | +3.02% | |
| Form 8-K Eton Pharmaceuticals, For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | +3.02% | |
| Eton Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.58% | +4.20% | |
| Form 10-Q Eton Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.58% | +4.20% | |
| Form 8-K Eton Pharmaceuticals, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.58% | +4.20% | |
| Eton Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +4.44% | |
| Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 | Press release | GlobeNewswire | +0.84% | +0.43% | |
| Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | Press release | GlobeNewswire | +5.44% | +17.38% | |
| Form 8-K Eton Pharmaceuticals, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -0.48% | +7.04% | |
| Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 | Press release | GlobeNewswire | -1.48% | +1.96% | |
| Form 8-K Eton Pharmaceuticals, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -1.48% | +1.96% | |
| Form DEF 14A Eton Pharmaceuticals, For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -1.48% | +1.96% | |
| Eton Pharmaceuticals Announces CFO Succession Plan | Press release | GlobeNewswire | -2.32% | -6.18% | |
| Form 8-K Eton Pharmaceuticals, For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -2.32% | -6.18% | |
| Form 8-K Eton Pharmaceuticals, For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | -2.32% | -6.18% | |
| Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -2.64% | +4.30% | |
| Form 10-K Eton Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.64% | +4.30% | |
| Form 8-K Eton Pharmaceuticals, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -2.64% | +4.30% | |
| Form S-8 Eton Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +1.90% | +0.54% | |
| Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 | Press release | GlobeNewswire | -0.34% | -0.51% | |
| Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution | Press release | GlobeNewswire | +2.87% | +6.45% | |
| Form 8-K Eton Pharmaceuticals, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +2.87% | +6.45% | |
| Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution | Press release | GlobeNewswire | — | -0.23% | |
| Form 8-K Eton Pharmaceuticals, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | — | -8.17% | |
| Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th | Press release | GlobeNewswire | -0.88% | -1.27% | |
| Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate | Press release | GlobeNewswire | +1.05% | -0.07% | |
| Form 8-K Eton Pharmaceuticals, For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +1.05% | -0.07% | |
| Form 8-K Eton Pharmaceuticals, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | +1.51% | |
| Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th | Press release | GlobeNewswire | +0.56% | +1.24% | |
| Form S-8 Eton Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.12% | -2.86% | |
| Form 8-K/A Eton Pharmaceuticals, For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | -2.15% | |
| Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th | Press release | GlobeNewswire | +0.98% | — | |
| Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -5.49% | -11.70% | |
| Form 10-Q Eton Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.49% | -11.70% | |
| Form 8-K Eton Pharmaceuticals, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -5.49% | -11.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ETON section they belong to.
Where else ETON is measured.
ETON earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Rockwell Medical, Inc. (RMTI) | 235 | +0.40% | 57% |
| Equillium, Inc. (EQ) | 234 | 0.00% | 51% |
| THERAPIX BIOSCIENCES LTD AMERICAN DEPOSITARY SHARE (TRPX) | 234 | -1.05% | 31% |
| Catalent, Inc. (CTLT) | 232 | +0.10% | 62% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Eton Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ETON news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 234 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of ETON's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ETON's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.